Morgan Stanley reiterates Celsius Holdings stock rating at Overweight By Investing.com

Q4 2025 EPS of $0.26 beat the $0.19 forecast by 36.8% and revenue was $722M, 12.9% above the $639.14M estimate. Morgan Stanley reiterated an Overweight with a $64 PT (stock $43.21, ~48% upside) while UBS raised its PT to $72 from $70 and Jefferies remains Buy; the shares trade at a high P/E of 176.5. Near-term Nielsen scanner data show deceleration (total energy drink sales +20% vs +31% prior two-week period; Brand Celsius growth slowed to 1.1% from 7.5%, dollar share down 70bps to 18.9%), prompting MS to lower its staples sector preference amid post-Iran demand risk.

Analysis

Retail-level slowdown in short-window scanner reads is a noisy signal rather than a definitive demand shift — two-week slices amplify promotional timing, new-SKU recognition lags, and Nielsen capture gaps for limited-time offers. The durable upside for challenger brands comes from share gains in high-frequency channels (c-store, grocery) where distribution density and velocity improvements compound revenue faster than outlet-level price increases.

Second-order supply-side effects matter: rapid distribution rollouts stress co-packers, aluminum can allocations, and inbound sweetener inventories, which can create episodic out-of-stocks that both lopsidedly depress reported scanner growth and force margin-dilutive spot buys. Incumbents with deeper broker networks can neutralize challengers via targeted slotting and promo funding, so execution of in-store resets and trade spend cadence will be the decisive next-12-month variable.

Valuation is a binary lever — with expectations embedded, misses cascade while operational wins re-rate quickly. Watch leading indicators (weekly household penetration, repeat-purchase rate, retailer reorders, and on-shelf availability) rather than headline two-week comps; a 6–12 week trend in these metrics is a better predictor of a durable recovery or further deceleration.

Key Decisions for Investors

• Long CELH LEAPs (18–24 months): Buy CELH Jan-2028 calls to capture a re-rate if distribution-driven velocity and repeat rates exceed current scanner noise; target 2.5x return if Nielsen-adjusted weekly velocity recovers within 6–9 months. Risk: premium decay and execution misses; position size capped at 1–2% portfolio, stop if repeat rate fails to improve after 9 months.
• Pair trade — long CELH / short MNST (6–12 months): Equal-dollar long CELH vs short MNST to isolate share and execution risk; asymmetric payoff if challenger sustains higher new-store velocity. Risk/reward: breakeven if CELH underperforms incumbent by ~10% relative; haircut max 3% of portfolio on adverse divergence.
• Defined-risk downside hedge on CELH (3 months): Buy a put spread to protect against a 20–35% near-term correction driven by scanner downgrades or retailer destocking (buy 3-month put / sell deeper put). Capital outlay limited to premium; payoff scales if a catalyst (earnings shortfall or distribution pullback) materializes.
• Long packaging supplier exposure (12 months) — BLL: Buy Ball Corp to play continued RTD and energy-drink can demand if category expansion persists; this is an indirect, lower-volatility way to capture upside from higher beverage unit growth. Risk: commodity-driven margin compression; target 15–25% upside versus 10% drawdown stop.